Jun 5 |
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
|
May 22 |
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
|
May 14 |
MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript
|
May 14 |
MiNK Therapeutics reports Q1 results
|
May 14 |
MiNK Reports First Quarter 2024 Results
|
May 13 |
Why MiNK Therapeutics Stock Is Up 11% Monday
|
May 13 |
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
|
Apr 30 |
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
|
Apr 11 |
This MiNK Therapeutics Insider Increased Their Holding In The Last Year
|
Apr 8 |
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
|